fda warning glp-1 compounding september 2025 Compounded" drugs | Health Communication Research Laboratory Have patients been harmed by

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

Common nutritional concerns associated with GLP-1 therapy may include: Reduced appetite and inadequate nutrient intake Loss of lean muscle mass during rapid weight reduction Nausea, digestive discomfort, and poor food tolerance Fatigue and reduced energy levels Micronutrient deficiencies over long-term use Increased nutritional needs in patients with complex clinical conditions Effective GLP-1 treatment requires more than medication alone

REDUCE HUNGER & CRAVINGS: Patented and clinically-studied Supresa saffron extract is shown to reduce hunger and snacking in as early as 8 weeks in clinical study participants. SUPPORT WEIGHT MANAGEMENT: Clinically-tested Morosil red orange extract is shown to support fat reduction, reduce BMI and combat visceral fat (in combination with diet and exercise) in clinical study participants. The product is formulated to support healthy weight management

Rated 4.5/5

GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro arent just trending topicstheyre fundamentally reshaping the world of weight loss and client coaching